Navigation Links
EntreMed Presents Mechanism Data for Its Three Lead Oncology,Compounds

Multiple Mechanisms for Panzem NCD, MKC-1, and ENMD-1198 Highlighted at Oncology Drug Discovery Conference

ROCKVILLE, Md., March 26, 2007 /PRNewswire-FirstCall/ -- EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of comparative mechanism of action data for its three lead clinical stage compounds Panzem(R), MKC-1 and ENMD-1198. These data were presented by Dr. Theresa M. LaVallee, EntreMed's Senior Director, Cell Biology in an oral podium session during the Apoptosis in Drug Discovery Conference, March 22-23, 2007 in San Diego, CA.

Panzem(R), MKC-1 and ENMD-1198 are three orally available agents that exhibit antiproliferative activity through G2/M arrest, apoptosis and antiangiogenesis. In preclinical models, these compounds are not sensitive to multi-drug resistance pumps and show activity in both vinca and taxane resistant tumor cell lines. While these three agents all bind to the colchicine-binding site of tubulin, they have distinct mechanisms of action. Panzem(R) has a well tolerated safety profile that lends itself to combination therapy with many other chemotherapeutic agents. In addition to binding tubulin, MKC-1 binds to importin-beta and inhibits signaling through the PI3K- Akt-mTor pathway. The PI3K-Akt-mTor pathway is frequently activated in cancer and has been shown to promote tumorigenesis. In an orthotopic animal model of human breast cancer, ENMD-1198 led to the disruption of microtubules within tumor cells and a substantial decrease in tumor cell proliferation and angiogenesis. The mechanisms of action of these three tubulin agents was compared and contrasted during the presentation.

Microtubules are key components of the cell structure and are essential for maintenance of cell shape, cellular functions and cell division (growth). These highly dynamic filaments are composed of dimeric tubulin proteins. Microtubule targeting drugs are one of the most successful classes of chemotherapy agents and are used for both solid and liquid tumors. There are three drug binding sites on tubulin: the vinca binding domain, the taxol- binding site and colchicine-binding site. The vinca alkaloids destabilize microtubules. The taxanes bind to the taxol-binding site and stabilize microtubules. While vincas and taxanes are widely used for treating cancer, there is a need to develop orally available molecules that have reduced toxicity and overcome resistance to approved chemotherapeutic agents.

Carolyn F. Sidor, M.D., M.B.A., EntreMed Vice President and Chief Medical Officer, commented on the results, "EntreMed is focused on developing multi- mechanism drugs for the treatment of cancer that have both antiproliferative and antiangiogenic properties. Tubulin binding and subsequent microtubule disruption are common mechanisms of our three lead compounds, yet clinical and preclinical data for these product candidates demonstrate that subtle differences in microtubule dynamics can lead to different approaches to the treatment of cancer. Panzem(R), MKC-1 and ENMD-1198 are all orally-active yet distinct tubulin binding agents, and exhibit a different array of antitumor activity preclinically. Understanding the multiple mechanisms of these drug candidates will help guide our selection of clinical indications and biomarkers. Panzem(R) NCD and MKC-1 are currently in multiple Phase 2 clinical trials for cancer and ENMD-1198 is in Phase 1 trials in advanced cancer patients."

To view the presentation, visit Scientific Presentations under the Therapeutic Pathways section of the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflam mation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell cycle regulator, is in Phase 2 studies for cancer. ENMD-1198, a novel tubulin binding agent, is also in Phase 1 studies in advanced cancers. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's website at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the integration of Miikana and its product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

    CONTACT:

    Ginny Dunn

    Associate Director, Corporate Communications & Investor Relations

    EntreMed, Inc.

    240-864-2643

CONTACT: Ginny Dunn, Associate Director, Corporate Communications &Investor Relations of EntreMed, Inc., +1-240-864-2643

Web site: http://www.entremed.com/

Ticker Symbol: (NASDAQ-NMS:ENMD)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Clinical Results From EntreMeds Panzem NCD and Taxol Breast Cancer Study Presented at ASCO
2. Phase 2 Results for EntreMeds Panzem NCD Brain Cancer Study Presented at ASCO
3. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
4. EntreMed Presents Preclinical Data for MKC-1 in Hematological Cancers
5. EntreMed Presents Multi-Mechanism Results for ENMD-1198 at AACR Annual Meeting
6. EntreMed Presents Multi-Mechanism Antitumor Data for ENMD-1420 in Preclinical Models
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
9. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
10. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
11. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
Breaking Medicine News(10 mins):